Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹114.72
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹3.50B
Enterprise Value₹4.01B
Total Cash (Recent Filing)₹331.50M
Total Debt (Recent Filing)₹462.12M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
API Manufacturing BusinessManufacturing APIs is a structurally resilient business: APIs are essential inputs for finished drugs, supporting steady industrial demand and long sales cycles. This core positioning gives durable revenue potential from contract manufacturing and repeat customers over the next 2–6 months and beyond.
Modest Leverage / Solid Equity BaseA large equity base versus modest debt gives financial flexibility to absorb near-term shocks, refinance if needed, and fund operational recovery or targeted investments. This reduces bankruptcy risk and supports medium-term strategic options without immediate refinancing stress.
Revenue Rebound In FY2026A meaningful top-line recovery indicates regained demand or successful commercial actions. If sustained, improving revenue provides a foundation to restore gross margins and leverage fixed costs, helping profitability normalize over several quarters rather than being a one-off.
Bears Say
Weak Cash GenerationNegative operating and free cash flow are structural constraints: they force reliance on external financing or equity to fund working capital and capex, limit reinvestment in capacity, and raise liquidity risk if negative trends persist across multiple quarters.
Unprofitable OperationsSustained losses erode retained earnings and reduce the company’s ability to self-fund growth or buffer downturns. Near-zero operating profit despite revenue rebound implies margin pressure or cost issues that must be resolved to achieve durable profitability.
Volatile Returns On EquityLarge swings in ROE reflect earnings volatility and execution or demand cyclicality. This undermines predictability for investors and management planning, complicates capital allocation, and increases the risk that improvements may reverse if underlying issues aren't addressed.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹114.72 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹3.50B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 43 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.32.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―